Moderna Finishes Enrolling 30,000 Patients For Coronavirus Vaccine Trial

CAMBRIDGE (CBS) – Moderna is one step closer to completing its coronavirus vaccine trial.

The Cambridge-based company said Thursday it has officially enrolled all 30,000 participants in the third phase of the trial, which involves two shots of the vaccination.

Right now, 25,654 (85-percent) of them have received the second dose.

Once everyone has the second vaccination, Moderna will take two months to assess the safety of it. If the benefits outweigh the risks, the company will then submit a request to the FDA to start emergency use of the vaccine. That would be given to frontline medical workers and other at-risk people first.

Moderna hopes the federal government could give approval for emergency use by the end of the year.

 

Read more
f

We and our partners use cookies to understand how you use our site, improve your experience and serve you personalized content and advertising. Read about how we use cookies in our cookie policy and how you can control them by clicking Manage Settings. By continuing to use this site, you accept these cookies.